Publications by the researcher in collaboration with Ángel Carracedo Álvarez (158)

2024

  1. Meta-analysis of genome-wide association studies for cancer therapy-related cardiovascular dysfunction and functional mapping highlight an intergenic region close to TP63

    Scientific Reports, Vol. 14, Núm. 1

  2. Novel risk loci for COVID-19 hospitalization among admixed American populations

    eLife, Vol. 13

  3. Role of CYP2D6 and CYP3A4 polymorphisms on aripiprazole and dehydroaripiprazole concentrations in patients undergoing long-acting treatment

    Progress in Neuro-Psychopharmacology and Biological Psychiatry, Vol. 135

  4. Towards precision medicine of long-acting aripiprazole through population pharmacokinetic modelling

    Psychiatry Research, Vol. 333

2023

  1. A second update on mapping the human genetic architecture of COVID-19

    Nature

  2. Detection of the Copy Number Variants of Genes in Patients with Familial Cardiac Diseases by Massively Parallel Sequencing

    Molecular Diagnosis and Therapy, Vol. 27, Núm. 1, pp. 105-113

  3. Differences in Patterns of Stimulant Use and Their Impact on First-Episode Psychosis Incidence: An Analysis of the EUGEI Study

    Schizophrenia Bulletin, Vol. 49, Núm. 5, pp. 1269-1280

  4. The relationship between genetic liability, childhood maltreatment, and IQ: findings from the EU-GEI multicentric case–control study

    Social Psychiatry and Psychiatric Epidemiology, Vol. 58, Núm. 10, pp. 1573-1580

2022

  1. Novel genes and sex differences in COVID-19 severity

    Human molecular genetics, Vol. 31, Núm. 22, pp. 3789-3806

2021

  1. Association of variants in MYH7, MYBPC3 and TNNT2 with sudden cardiac death-related risk factors in Brazilian patients with hypertrophic cardiomyopathy

    Forensic Science International: Genetics, Vol. 52

  2. Obesity-related genetic determinants of stroke

    Brain Communications, Vol. 3, Núm. 2

  3. Review of pharmacokinetics and pharmacogenetics in atypical long-acting injectable antipsychotics

    Pharmaceutics, Vol. 13, Núm. 7

  4. The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study

    Translational Psychiatry, Vol. 11, Núm. 1

2020

  1. A multicentre prospective study evaluating the impact of proton-pump inhibitors omeprazole and pantoprazole on voriconazole plasma concentrations

    British Journal of Clinical Pharmacology, Vol. 86, Núm. 8, pp. 1661-1666

  2. Anti-VEGF treatment and response in age-related macular degeneration: Disease’s susceptibility, pharmacogenetics and pharmacokinetics

    Current Medicinal Chemistry, Vol. 27, Núm. 4, pp. 549-569

  3. Genetic variants of uncertain significance: How to match scientific rigour and standard of proof in sudden cardiac death?

    Legal Medicine, Vol. 45

  4. Impact of CYP2C19 Genotype and Drug Interactions on Voriconazole Plasma Concentrations: A Spain Pharmacogenetic-Pharmacokinetic Prospective Multicenter Study

    Pharmacotherapy, Vol. 40, Núm. 1, pp. 17-25

  5. Interaction between the functional SNP rs2070951 in NR3C2 gene and high levels of plasma corticotropin-releasing hormone associates to postpartum depression

    Archives of Women's Mental Health, Vol. 23, Núm. 3, pp. 413-420

  6. Polygenic risk score as a key factor in cardiovascular clinical prediction models

    Revista Espanola de Cardiologia, Vol. 73, Núm. 8, pp. 608-610

  7. Premorbid Adjustment and IQ in Patients with First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship with Cannabis Use

    Schizophrenia Bulletin, Vol. 46, Núm. 3, pp. 517-529